Pharmaceutical brand name corporations are pushing hard so that the revised EU legislation provides for prolongation of "data protection" and "commercial exclusivity" for their products.
You’ll find Medicines in Europe Forum position on this issue in the attached PDF.
For more information click here.
Was this article interesting and relevant
for you? Do you have any comments?
The European Public Health Alliance runs projects which receive financial support from the European Commission. The views expressed in this website do not necessarily reflect the official views of the EU institutions.
This website is powered by open source solutions and runs on a Linux server.
